Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.00 - $10.66
Previous CloseN/A
Volume91.62K
Average Volume (3M)376.76K
Market Cap
$232.71M
Enterprise Value$38.42M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)5.9
Beta1.05
Next Earnings
Mar 11, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding54,625,587
10 Day Avg. Volume465,122
30 Day Avg. Volume376,759
Standard Deviation0.22
R-Squared0.05
Alpha-0.00311
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.16
Enterprise Value/Ebitda2.72
Forecast
1Y Price Target
$16.20Price Target Upside280.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityTermination of VY9323 extends VYGR cash runway into mid-2027, providing more financial flexibility.
Pipeline DevelopmentVoyager's pipeline is nearing a breakout with multiple CNS-targeting gene therapies nearing IND filings.
Platform ViabilityThe tau AAV program showed no neurotoxicity at doses corresponding to reasonable tau lowering, suggesting the platform is still viable.
Bears Say
Clinical DelaysVoyager Therapeutics no longer anticipates an IND filing for VY9323 in mid-2025, indicating a delay in their program timeline.
Safety ConcernsVYGR announced discontinuation of the development of its pre-clinical SOD1 silencing gene therapy candidate for ALS due to neurotoxicity at high doses.
Therapeutic WindowThere does not seem to be a sufficiently wide therapeutic window for VY923 with the current payload.
---
Ownership Overview
2.35% Insiders
13.29% Mutual Funds
30.19% Other Institutional Investors
43.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $4.00 and its highest was $10.66 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $232.71M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 17 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.285.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 54,625,587 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went down -2.05%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
---
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (280.28% Upside)
$16.20 (280.28% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $96.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.72%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
44.59%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
---
VYGR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant advancements in partnerships, financial stability, and Alzheimer's research. However, challenges in clinical trial outcomes and patient selection were noted. Overall, there is optimism about the potential of their pipeline and strategic partnerships.Read More>---
VYGR Stock 12 Month Forecast
Average Price Target
$16.20
▲(280.28% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering VYGR
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+1.87%
reiterated a buy rating 3 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +1.87% per trade.
---